Thus, in allogeneic settings, an mTOR inhibitor such as Rapa is a better choice for adjunct therapy with IL-2 in expansion of Tregs and protection against allogeneic BMT-induced GVHD. This evidence concerns the gene IL2 and graft versus host disease.